Keith P. Thompson MDFounder and CEODigitalVision SystemsKeith P. Thompson MD, is an internationally recognized refractive surgeon and an expert in physiological optics and vision correction technologies. Thompson completed his ophthalmology residency at the Bascom Palmer Eye Institute in Miami followed by a National Eye Institute sponsored Fellowship where he studied corneal, refractive surgery, and physiological optics at Emory University in Atlanta. During his fellowship, Thompson collaborated with researchers at Harvard and MIT to develop spatially resolved refactometry, a novel method for determining refractive measurements through different regions of the pupil. As a Professor of Ophthalmology at Emory, Thompson was one of the lead US clinical investigators in the FDA clinical trials of PRK and LASIK. Thompson and his colleagues at Emory co-founded one of the first laser vision surgery centers in the United States where they conducted the first FDA supervised trial of LASIK surgery presented to the FDA’s Ophthalmic Device Panel in 1997.
During his clinical trials experience, Thompson came to recognize that poor clinical outcomes were often caused by the fundamental limitations in the accuracy and resolution of phoropter measurements. Thompson and DVS co-founder Jose Garcia continuously improved and evolved the SRR technology into new device for replacing the phoropter known as the VisionOptimizer. In 2009, DVS was selected as a VentureLab Company, a Georgia Tech program that provides economic support to startup companies developing technology deemed to have commercial potential. Working with optical engineers at Georgia Tech’s Electro-Optical Systems Lab, the DVS team is completing a fully functional prototype of the VisionOptimizer that will enter clinical trials at Georgia Tech in the Spring of 2013. The DVS team has demonstrated that the VisionOptimizer has the potential to improve eyesight over error-prone phoropter and it is the first technology capable of demonstrating the optical features of any type of corrective product to patients under natural viewing conditions.